Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease (ILD-DLCO)
Double-Blind, Placebo-Controlled Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease
Sponsor: Diffusion Pharmaceuticals Inc
Terminated
Due to, among other things, positive results from the 200-302 trial, the trial has been terminated early. Resources shifted to new 200-208 GBM trial using information gained from 200-302.
Other terminated trials from Diffusion Pharmaceuticals Inc
- Glioblastoma · Phase PHASE3 · Nov 2020
- Stroke, Acute · Phase PHASE2 · Oct 2020
- High Grade Glioma · Phase PHASE1 · May 2009
More terminations from Diffusion Pharmaceuticals Inc
Other Interstitial Lung Disease trials with similar outcome
This PHASE2 trial investigates Interstitial Lung Disease and is currently terminated or withdrawn. Diffusion Pharmaceuticals Inc leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Diffusion Pharmaceuticals Inc
For direct contact, visit the study record on ClinicalTrials.gov .